文献速递前列腺癌

自动骨扫描指数作为预测Zometa欧洲研究/SPCG11总生存的影像生物标志物

Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.
PubMed 文献 · Eur Urol Oncol · 2019-06-08

本研究回顾性纳入Zometa欧洲研究(ZEUS)/SPCG11中基线与48个月随访时影像质量足以评估自动骨扫描指数(aBSI)的高危前列腺癌患者,使用EXINIboneBSI软件盲法计算aBSI。aBSI变化≤0.3的患者中位生存显著长于变化>0.3者(p<0.0001),aBSI升高与总生存显著相关(p<0.01,C-index=0.65),而年龄和PSA变化无显著关联。

要点

  • aBSI变化≤0.3者中位生存显著长于变化>0.3者(p<0.0001)。
  • aBSI升高与总生存显著相关(p<0.01,C-index=0.65)。
  • 年龄和PSA变化与总生存无显著关联。

核心结论

  • aBSI作为客观影像生物标志物可预测ZEUS/SPCG11研究中前列腺癌患者的结局。
  • 基线至48个月随访的aBSI变化是骨转移前列腺癌患者预后和监测的有价值工具。

研究设计与样本

  • 回顾性选取ZEUS/SPCG11研究中基线与48个月随访影像质量足以评估aBSI的全部患者。
  • 使用EXINIboneBSI软件计算aBSI,对临床数据和唑来膦酸治疗随机化设盲。

主要发现

  • 176例骨转移患者中,aBSI变化≤0.3者中位生存时间显著长于aBSI变化>0.3者(p<0.0001)。
  • aBSI升高与总生存显著相关(p<0.01,C-index=0.65)。
  • 年龄和PSA变化与总生存无显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Owing to the large variation in treatment response among patients with high-risk prostate cancer, it would be of value to use objective tools to monitor the status of bone metastases during clinical trials. Automated Bone Scan Index (aBSI) based on artificial intelligence has been proposed as an imaging biomarker for the quantification of skeletal metastases from bone scintigraphy. OBJECTIVE: To investigate how an increase in aBSI during treatment may predict clinical outcome in a randomised controlled clinical trial including patients with high-risk prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively selected all patients from the Zometa European Study (ZEUS)/SPCG11 study with image data of sufficient quality to allow for aBSI assessment at baseline and at 48-mo follow-up. Data on aBSI were obtained using EXINIboneBSI software, blinded for clinical data and randomisation of zoledronic acid treatment. Data on age, overall survival (OS), and prostate-specific antigen (PSA) at baseline and upon follow-up were available from the study database. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Association between clinical parameters and aBSI increase during treatment was evaluated using Cox proportional-hazards regression models, Kaplan-Meier estimates, and log-rank test. Discrimination between prognostic variables was assessed using the concordance index (C-index). RESULTS AND LIMITATIONS: In this cohort, 176 patients with bone metastases and a change in aBSI from baseline to follow-up of ≤0.3 had a significantly longer median survival time than patients with an aBSI change of >0.3 (p<0.0001). The increase in aBSI was significantly associated with OS (p<0.01 and C-index=0.65), while age and PSA change were not. CONCLUSIONS: The aBSI used as an objective imaging biomarker predicted outcome in prostate cancer patients in the ZEUS/SPCG11 study. An analysis of the change in aBSI from baseline to 48-mo follow-up represents a valuable tool for prognostication and monitoring of prostate cancer patients with bone metastases. PATIENT SUMMARY: The increase in the burden of skeletal metastases, as measured by the automated Bone Scan Index (aBSI), during treatment was associated with overall survival in patients from the Zometa European Study/SPCG11 study. The aBSI may be a useful tool also in monitoring prostate cancer patients with newly developed bone metastases.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Reza M, Wirth M, Tammela T, et al. Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. Eur Urol Oncol. 2019. PMID: 31186177. doi:10.1016/j.euo.2019.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。